Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo covers the period ending July 21, 2004. The report incorporates two press releases: one dated July 20, 2004, regarding a regulatory filing by a third party, and another dated July 21, 2004, announcing sales figures for the first half of 2004.
Key Financial Metrics
The filing text references the announcement of sales figures for the first half of 2004 in Exhibit 99.2 but does not provide the specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this document. The filing text does not provide a clear value for these metrics.
Material Changes and Unusual Items
- Regulatory Development: On July 20, 2004, Sanofi-Synthelabo confirmed that Teva Pharmaceuticals filed an Abbreviated New Drug Application (ANDA). This indicates a potential competitive threat or generic entry for a Sanofi product.
- Sales Announcement: The company released first-half 2004 sales data on July 21, 2004, though the specific figures and year-over-year comparisons are not detailed in this summary text.
Guidance, Outlook, and Risks
The filing does not contain explicit forward-looking guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the confirmation of the ANDA filing by Teva Pharmaceuticals. The document serves primarily as a vehicle to incorporate the referenced press releases by reference.
Investor Verification Checklist
- Verify the specific first-half 2004 sales figures and growth rates in the full text of the July 21, 2004 press release (Exhibit 99.2).
- Identify the specific Sanofi product for which Teva Pharmaceuticals filed the ANDA to assess potential revenue impact.
- Review the full press releases for any management commentary on the competitive landscape or strategic response to the ANDA filing.